Trovagene Shares Rising Tuesday Following Preclinical Data Release
23 April 2019 - 9:22PM
Dow Jones News
By Stephen Nakrosis
Shares of Trovagene, Inc. (TROV), an oncology therapeutics
company, are rising in Tuesday's market after the company released
preclinical data which indicated a combination of its onvansertib
with venetoclax in an acute myeloid leukemia cell model known to be
resistant to venetoclax demonstrated synergy with a significant
decrease in tumor cell viability.
At 2:45 p.m. ET, the company's shares had risen 13.76% to trade
at $3.72. Volume was high, with over 7.1 million shares trading,
surpassing the 65-day average volume of just over 1 million. The
company has a public float of 4 million shares.
AbbVie Inc. (ABBV) makes venetoclax. That company's stock was up
1.09% on the day, to trade at $79.01.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 23, 2019 15:07 ET (19:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
